Inovio Pharmaceuticals (INO)
(Real Time Quote from BATS)
$8.83 USD
-0.26 (-2.86%)
Updated Jun 17, 2024 11:36 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 241 - 260 ( 364 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Hold Response Submitted; VGX-3100 Phase 3 Trial Starting This Quarter; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2016 Financial Results Reported; VGX-3100 Phase 3 Trial Starting in 1H 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MERS and Zika Vaccines Advance in Phase 1 Trials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Zika Vaccine Produced Robust Immune Response in Phase 1 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Financial Results; Reiterate Buy and Adjusting Price Target to $13
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 Trial of VGX-3100 Delayed to 1H 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.